BioAtla BCAB
OTC BCAB
$1.45 +0.12 (+9.02%)
As of: Oct 21, 2026 · 12:24 PM EDT

BioAtla (BCAB) Receivables - Net (2026)

Updated

BioAtla (BCAB) reported Receivables - Net of $2 million for Q2 2026.

Analysis

BioAtla (BCAB) Receivables - Net (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 BioAtla 2.41 Mn -16.54 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.00 Mn
API Access

BioAtla Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=BCAB&period=max&api_key=YOUR_API_KEY